The Dermatology Digest

JULY 1, 2024

The FDA’s approval of PYZCHIVA is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency. PYZCHIVA, developed by Samsung Bioepis, will be commercialized by Sandoz in the United States.

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

Aesthetics Advisor

SEPTEMBER 15, 2023

The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. This study is expected to wrap up by February 2023. As of June 2023, several COVID-19 nasal spray vaccines are being researched in studies — 16 intranasal and 2 inhaled to be exact.

Hospital 69

Hospital Clinic Marketing Medical 69

The Eco Well Blog

MAY 8, 2023

He’s held key R&D, regulatory, quality, product safety, clinical & scientific affairs positions at Ciba, Dial, Henkel, ITG Brands, Newell Rubbermaid. He’s been active in helping shape & influence Congressional cosmetic and OTC drug legislative reform initiatives.

Legal 52

Legal Technology Sun Protection Branding 52